| INTRODUCTION
Eosinophilic oesophagitis (EoE) is a chronic immune/antigenmediated clinicopathologic disorder defined histologically by eosinophilic-predominant oesophageal inflammation and clinically by oesophageal dysfunction. It is diagnosed when there are at least 15 eosinophils per high-power field (eos/hpf) on oesophageal biopsies and after exclusion of alternative aetiologies of eosinophilia.
1,2 EoE represents a major cause of oesophageal morbidity. [3] [4] [5] The pathogenesis of EoE is multi-factorial, but clinical, histological, and endoscopic improvement with dietary elimination strategies supports the role of food antigen sensitisation in the aetiology of the disorder. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] While corticosteroids improve both the clinical and histological features of EoE, 18, 19 there are appreciable rates of nonresponse to steroids, 20, 21 side-effects are possible, 20, [22] [23] [24] [25] [26] and EoE disease activity recurs after discontinuation of these drugs. 27, 28 In contrast, food elimination diets (FEDs) address the aetiologic triggers of EoE, lack adverse side effects associated with medication, and may produce long-term remission. This makes dietary elimination an attractive treatment option. However, as compared with children, little is known about the long-term efficacy of this treatment strategy in adults. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] Therefore, this study aimed to assess the overall long-term efficacy of FEDs in adults for treatment of EoE. We also aimed to evaluate the effectiveness of a FED in patients previously treated for EoE with topical steroids.
| MATERIALS AND METHODS
We conducted a retrospective cohort study at the University of North Carolina (UNC) Hospitals from 2008 to 2017. The UNC institutional review board approved this study. Cases of EoE were diagnosed per consensus guidelines 1, 2 and identified from the UNC EoE Clinicopathologic database. The UNC EoE Clinicopathologic database was previously described. 29 Included EoE patients were 18 years or older at the time a FED was started, had no use of EoE-specific medications concurrently or within 6 weeks of FED, and had subsequent follow-up at UNC including endoscopy with biopsy. Patients with eosinophilic infiltration of additional segments of the gastrointestinal tract were also excluded from this study.
To help isolate the effect of a FED, data were abstracted from treatment periods when patients received a FED without concomitant steroids or second-line EoE therapies. However, patients who were previously treated with corticosteroids or a second-line therapy were not excluded from the analysis. The standard of practice at UNC allows at least 4 weeks off steroids prior to FED initiation.
Also, to help minimise misclassification and measurements biases, we did not analyse treatment intervals when patients were lost to follow-up.
Two predominant strategies existed for initiating dietary elimination therapy over the study interval. The first strategy was targeted elimination therapy. Patients treated with targeted elimination underwent skin and/or radioallergosorbent testing, and foods with a positive reaction, as well as those identified from patient self-report as possible triggers, were eliminated from the diet. The second main strategy was an empiric 6-food elimination diet (6FED) for which patients eliminated dairy, wheat, eggs, soy, nuts and seafood. In a minority of patients, a 6FED was combined with additional targeted elimination of presumptive food triggers. All patients were offered consultation with a dietician, and most had at least one visit during which the specific diet was reviewed, nutritional information on alternatives to the eliminated food groups was provided, and additional published handouts and resources were given. 30, 31 After instituting dietary elimination, the clinical protocol was to repeat an upper endoscopy to assess endoscopic and histological response after 6 weeks of treatment. For patients who had histological response to a FED, defined as oesophageal biopsies with <15 eos/ hpf, 32,33 one food group was added back for 6 weeks, and endoscopy was repeated. This process was iterative and continued until all foods had been added back, which allowed for identification of specific triggers of EoE.
The FED of a minority of patients was modified or changed, as the diet did not produce a histological response at the first posttreatment endoscopy (eg, additional targeted elimination of suspected food triggers added to a 6FED). For the purposes of this paper, in these specific patients, the baseline symptomatic, endoscopic and histological data refer to findings before the initiation of any FED. Treatment responses were abstracted after the initiation of the second/modified (or most restrictive) dietary elimination strategy. at baseline or follow-up assessments.
The mean age at the start of dietary elimination was 38.5 years, and most patients were female (60%) and white (92%) ( Table 1) . Formal food allergen testing, whether by patch, prick, or radioallergosorbent testing, was completed in 63% of patients. Of those, 79% had at least one food sensitivity identified from testing. At baseline endoscopy, rings and furrows were the most common features, and the mean total EREFS score was 4.1. The mean peak eosinophil count prior to FED treatment was 60.3 eos/hpf (Table 1) . Prior to initiating a FED, there were 42 (81%) patients who previously received corticosteroids, which were discontinued for primary nonresponse or loss of response in 15 (36%), and by patient preference in the remainder (Table 2) . Throughout the follow-up period, patients predominantly demonstrated partial to good adherence to a FED (94%).
| Initial response to FED
There were 32 patients (62%) who were treated with a targeted elimination diet, 18 (35%) treated with a 6FED, and 2 (4%) who were initiated on a combined 6FED plus targeted elimination diet (Table 2 ). There were nine patients in whom the initial FED was modified or changed, as they did not have a histological response at the first post-treatment endoscopy ( Table 2 ). Four were transitioned from a targeted diet to a 6FED; 1 was transitioned from a 6FED to a targeted diet with foods outside of the traditional six foods; two had a targeted diet added to a 6FED; and two patients had a 6FED
added to a targeted diet.
A total of 73% of subjects reported a global improvement in symptoms ( patients initially receiving a targeted elimination diet, and 2/2 patients initially receiving a combined 6FED and targeted elimination who had a histological response to therapy (P = .84). Of the 21 histological responders, eight (38%) were on a 6FED, 11 (52%) received targeted elimination and two (10%) received combined 6FED and a targeted elimination diet (P = .51). Among the nine patients previously described in whom an initial FED was modified or changed, only two (22%) achieved a histological response: one patient transitioned to a 6FED alone and one patient transitioned to a 6FED supplemented by a targeted elimination diet. Of the nonresponders, treatments were similarly distributed with 6FED (34%), targeted elimination (52%), and combined diets (14%). Histological responders and nonresponders did not differ significantly by adherence (81% vs 93% partial to good adherence in responders vs nonresponders; P = .65) nor did they differ substantially by prior corticosteroid exposure (74% nonresponders with previous exposure vs 81% responders with previous exposure; P = .88). When analysing patients with complete vs partial or non-adherence to a FED, the proportion of patients with and without histological responses did not differ (81% vs 81% complete adherence in responders vs non-responders; P = .98).
After the most restrictive diet, 94% of responders reported a global improvement in symptoms, and only 11% reported dysphagia (95% baseline vs 11%; P = .005). The total EREFS score and peak of the mean eosinophil count both significantly decreased from 3.2 to 0.7 (P = .001) and 49.8 to 4.1 eos/hpf (P = .001) respectively. For patients without a histological response, the mean of the peak eosinophil counts increased from 67.7 to 75.5 eos/hpf after the most restrictive FED (P = .82). In addition, 55% of non-responders indicated a global improvement in symptoms with 43% reporting dysphagia specifically (87% baseline vs 43%; P = .05). Nonresponders had a minimal and nonstatistically significant improvement in the total EREFS score (4.3 vs 4.0; P = .14), and none of the individual components of the EREFS severity scores improved after therapy in these patients.
| Long-term dietary elimination outcomes
Nineteen of the responders (90%) underwent serial reintroduction of foods with identification of an allergic trigger(s). The most commonly identified food trigger was dairy (53%) followed by wheat (37%) and eggs (26%). There were seven patients with a single food trigger, which was dairy in five cases ( Figure 4A ). For 10 patients, there
were two food triggers with wheat being a trigger in seven of 10. In addition, there were two patients with three or more food triggers.
Of these 19 patients, there were 12 (63%) who had undergone Initial food elimination diet strategy (%)
Six food elimination diet (n = 18) 35
Combined targeted + six food elimination diet (n = 2) 4
Modified diet after first nonresponse (n = 9) 17
Targeted diet to 6FED (n = 4) 6FED to targeted diet (n = 1)
Targeted diet added to 6FED (n = 2) 6FED added to targeted diet (n = 2)
LTA, leukotriene antagonist; H2A, histamine 2 receptor antagonist; 6FED, 6 food elimination diet. formal allergen testing. Formal allergen testing correctly identified a causative trigger in six patients (50%) ( Table 3) . There were nine patients treated with a targeted elimination diet in which a food trigger(s) was identified at the end of follow-up. Of interest, 5/9 (56%) had food antigens contained solely within a 6FED (eggs; wheat and eggs; wheat and dairy; soy, egg, seafood and nuts; dairy), 2/9 (22%) had at least one food trigger included within a 6FED ('soy' and chicken; dairy, 'nuts', and multiple berries), and 2/9 (22%) had no food triggers found within a 6FED (pork; oats and beef). Dairy and wheat were also identified as the sole food triggers in the two patients treated with combined 6FED and targeted elimination diet. Among the 15 patients with prior primary or secondary nonresponse to steroids, only 1 (6%) had a durable histological response to a FED, compared to 40% (4/10) in steroid-na€ ıve patients (P = .28). Of the 10 maintenance responders, 6 (60%) were initiated on a 6FED, and four (40%) were started on a targeted elimination diet. There was one (10%) maintenance responder for whom the initial FED strategy was modified. For this patient, the initial FED was transitioned from a 6FED to a 6FED with additional targeted removal of additional foods. At the end of follow-up, all but one patient opted to continue a FED rather than transition to an alternative therapy.
A global improvement in symptoms was documented for initial responders at the end of the follow-up period (67%) as well as for dysphagia individually (95% vs 33%; P = .008). Heartburn (37% vs 8%; P = .16) and chest pain (21% vs 0%; P = .08) trended towards durable improvements. Only one (8%) patient underwent oesophageal dilation during their final available endoscopy, compared with 27 (52%) prior to starting a FED (P = .06). Durable improvements were also documented for endoscopic findings for all initial responders at the end of follow-up. The total EREFS score was 1.7 compared to 3.2 at baseline (P = .06). In addition, the EREFS exudates For the initial histological responders, the mean of the peak eosinophil count was 31.3 eos/hpf at the end of the mean 24.9-month follow-up period, which compared with a pre-treatment peak eosinophil count of 49.8 eos/hpf (P = .17).
For the maintenance responders, dysphagia was significantly improved from pre-FED baseline (90% vs 14%; P = .03) ( Figure 2B) at the end of the follow-up period. These 10 patients also uniformly (100%) reported global improvement in symptoms. Additional upper gastrointestinal symptoms trended towards improvement at the end of follow-up for maintenance responders including chest pain (40% vs 0%; P = .08), abdominal pain (10% vs 0%; P = 1.00) and heartburn (40% vs 14%; P = .16). Component EREFS scores were decreased from baseline at the end of follow-up for maintenance responders but did not reach statistical significance ( Figure 2B ). The final available mean peak eosinophil count for the maintenance responders was 5.2 eos/hpf. This was a sustained improvement from their pre-FED peak eosinophil count of 44.4 eos/hpf (P = .02). The last available peak eosinophil count in the 11 initial responders with poor compliance or food reintroduction at the end of follow-up was 60.2 eos/hpf and similar to their pre-FED value of 55.8 eos/hpf (P = .83; Figure 3 ). In the maintenance non-responders, initial symptomatic and endoscopic improvements were attenuated. There were 5 (45%) maintenance non-responders reporting continued global symptomatic improvement. However, though not as pronounced for maintenance responders, dysphagia (91% vs 43%; P = .08), heartburn (36% vs 0%; P = .32, and abdominal pain (27% vs 14%; P = 1.0) all trended towards long-term improvements in histological nonresponders. The total EREFS severity score (3.2 vs 1.9; P = .14)
also trended towards a durable long-term improvement from baseline in the histological nonresponders.
| DISCUSSION
While dietary elimination therapy has been shown to be an effective treatment for EoE, there are few long-term outcome data in adults.
In this study, we aimed to determine the long-term clinical efficacy of FEDs in a cohort of adult patients with EoE. We found that dietary therapy resulted in sustained symptomatic, endoscopic and histological improvements in patients who remain compliant with eliminating known or suspected dietary triggers at a mean follow-up time of just over 2 years. In our study, only a minority of patients both responded to a FED and remained compliant with the diet throughout the 2-year follow-up of this cohort.
Elemental diets utilising liquid amino acid-based formulations, 7, 35 targeted elimination diets excluding foods based on allergy testing, [8] [9] [10] and empiric elimination diets excluding common food triggers without specific allergy testing [11] [12] [13] [14] have all been assessed as EoE treatments. A meta-analysis of studies of adults showed that elemental diets were effective in 91% of patients, empiric elimination diets in 72%, and allergy test-directed diets in 46%. 36 There are no randomised clinical trials pertaining to the use of dietary therapy in management of EoE. However, the data are strong and show excellent clinical and histological response rates. 37 When food triggers are removed, it is reasonable to conclude that patients can enter longterm remission that does not require medicinal therapy. However, until more recently, this had not been substantiated in an adult EoE cohort. 13, 17 Prior to 2013, no data informed the long-term clinical effectiveness of a FED for adult EoE patients but rather studies focused on the short-term ability of a FED to induce histological remission. 11, 14, 15 The first paper considering the long-term effectiveness of a FED analysed a prospective cohort study of 67 patients. 13 Similar to our data, this study demonstrated a sustained response in 15 adults who were followed up for a mean period of approximately 2 years. This was a prospective experimental study of European patients, and it is possible that the results may not generalise to a "real-world" US clinical cohort. In addition, this cohort was only exposed to a 6FED, and as such, these findings cannot be extrapolated to the long-term effectiveness of a targeted elimination diet. A similar study was published in 2016, which included 56 adult patients treated with 6FED, of whom 29 responded to 6FED. 17 Of these, 18 were followed up for a mean period of 9.6 months and, again, similar to our data, just 10 remained in remission.
The response rates seen in our study (73% global symptomatic response; 40% histological response <15 eos/hpf after the most restrictive FED) are numerically lower relative to previously reported data. However, as opposed to prior studies, our study included patients who pursued dietary therapy after previously failing corticosteroids. As such, our population may have more resistant disease, which is less likely to respond to any available treatment modality. In our real-world cohort, we documented that each shortterm responder maintained a long-term and durable histological response if adherence to known food allergens was maintained over a mean follow-up period of over 2 years. Unfortunately, this adherence occurred in only a minority of initial responders. In addition, durable and significant symptomatic and endoscopic improvements were recorded for all responders over the entire follow-up interval.
We also found that patients without a histological response to a FED reported improvements in symptomatic but not endoscopic endpoints. Given emerging natural history data suggesting that persistent oesophageal eosinophilic infiltration places EoE patients at risk for ongoing fibrotic remodelling of the oesophagus, 38, 39 our data emphasise the importance of assessing a histological endpoint when examining outcomes of dietary therapy in EoE.
Limitations exist for this study. As this project was done in a retrospective manner, data extraction relied on chart review. This introduces the potential for misclassification and measurement biases into the study. In addition, as data were not collected in a prospective manner and some data collection preceded the validation of symptom measures, standardised instruments were not used to abstract or record patient symptoms. As such, symptom findings should be interpreted with caution. This study also included patients who initiated a FED prior to widespread adoption of the EoE endoscopic reference scoring system, which permitted 25 paired comparisons after FED initiation and 10 paired comparisons at the end of the follow-up period. However, these missing data reduce the power of statistical tests but not the validity of our conclusions. There are also multiple strengths for this study. This study represents one of the larger cohort studies analysing dietary therapy in EoE. Unlike previously reported studies, we also included patients utilising a number of FED strategies. In addition, as these results were from outside a clinical trial and included prior steroid nonresponders, they may represent more of a "real-world" response that is indicative of routine clinical practice.
In conclusion, dietary elimination produced a durable symptomatic and endoscopic response in a real-world cohort of adult EoE patients followed up for more than 2 years. In addition, though adherence represents a real problem and limits the number of patients remaining on a FED long term, a sustained histological response was documented in patients compliant with avoiding dietary triggers. Among patients with an initial treatment response to a FED, the long-term data within this study confirm that dietary elimination produces a durable clinical response.
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